The Immunochemical Determination of Apolipoprotein A,Total Apolipoprotein A-I and ‘Free’ Apolipoprotein A-I in Serum of Patients on Chronic Haemodialysis
Free accessReview articleFirst published online July, 1984
The Immunochemical Determination of Apolipoprotein A,Total Apolipoprotein A-I and ‘Free’ Apolipoprotein A-I in Serum of Patients on Chronic Haemodialysis
We have determined by radial immunodiffusion the apolipoprotein A content of undelipidated serum samples from 30 patients on chronic haemodialysis and 28 controls using an antiserum against high density lipoprotein (anti-apolipoprotein A). We found that the patients had lower concentrations of apolipoprotein A than the controls. When an antiserum against apolipoprotein A-I was used and the samples were delipidated prior to radial immunodiffusion there was, however, no difference in the total amount of apolipoprotein A-I between the two groups. We were able to explain this difference by measuring the amount of ‘free’ apolipoprotein A-I after crossed immunoelectrophoresis of undelipidated samples, using the antiserum against apolipoprotein A-I. We found that the patients had a higher level of ‘free’ apolipoprotein A-I than the control group. Since apolipoprotein A-I inhibits hepatic triglyceride lipase, the increase in triglycerides observed in patients on haemodialysis may be caused by the greater concentration of ‘free’ apolipoprotein A-I in their serum.
References
1.
LindnerACharraBSherrardDJAccelerated atherosclerosis in prolonged maintenance hemodialysis. New Engl J Med1974; 290: 697–701.
2.
MillerGJMillerNE. Plasma high-density lipoprotein concentration and development of ischaemic heart disease. Lancet1975; i: 16–19.
3.
BrunzellJDAlbersJJHaasLBPrevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism1977; 26: 903–910.
4.
BagdadeJDAlbersJJ. Plasma high density lipoprotein concentrations in chronic hemodialysis and renal transplant patients. New Engl J Med1977; 296: 1436–9.
5.
RapoportJAviramMChaimovitzCDefective high density lipoprotein composition in patients on chronic hemodialysis. New Engl J Med1978; 299: 1326–9.
6.
DelavelleFTrombertJCBavereyEFacteurs de risque vasculaire de l'hémodialysé chronique. La Nouv Presse Méd1979; 8: 1485–9.
7.
NestelPJFidgeNHTanMH. Increased lipoprotein remnant formation in chronic renal failure. New Engl J Med1982; 307: 329–33.
8.
AlbersJJWarnickRCheungMC. Quantitation of high density lipoproteins. Lipids1978; 13: 926–32.
9.
ShapiroDBallantyneFCSheperdJ.Comparison of immunonephelometry and electroimmunoassay for estimation of plasma apoA-I. Clin Chim Acta1980; 103: 7–12.
10.
WeinstockNBartholomeMSeidelD.Determination of apolipoprotein A-I by kinetic nephelometry. Biochim Biophys Acta1981; 663: 279–88.
11.
RosseneuMVercaemstRVinaimontNQuantitative determination of human plasma apolipoprotein A-I by laser immunonephelometry. Clin Chem1981; 27: 856–9.
12.
SavdieEGibsonJCStewartJHHigh density lipoprotein in chronic renal failure and after renal transplantation. Br Med J1979; i: 928–30.
13.
MünscherGMetzmannEZiegenbeinW.Standardization procedures of immunochemical apolipoprotein quantitation. La Ricerca Clin Lab1982; 12: 143–54.
14.
AlaupovicP.Apolipoproteins and lipoproteins. Atherosclerosis1971; 13: 141–6.
15.
CurryMDAlaupovicPSuenramCA. Determination of apolipoprotein A and its constitutive A-I and A-II polypeptides by separate electroimmunoassays. Clin Chem1976; 22: 315–22.
16.
SchonfeldGChenJSRoyRG. Antigenic properties of apoA-I and apoA-II in intact HDL. J Biol Chem1977; 252: 6651–4.
17.
SchonfeldGChenJSRoyRG. Use of antibody specificity to study the surface disposition of apoprotein A-I on human HDL. J Biol Chem1977; 252: 6655–9.
18.
MaoSJTMillerJPGottoAMThe antigenic structure of apolipoprotein A-I in human HDL. J Biol Chem1980; 255: 3448–53.
19.
BørresenALBergK.Presence of ‘free’ apoA-I in serum: Implications for immunological quantification of HDL and its apoproteins. Artery1980; 7: 139–60.
20.
ClineLJCrowleAJ. Identification of α1-lipoproteins in crossed immunoelectrophoresis. Clin Chem1979; 25: 1749–56.
RemanFCVermondA.The quantitative determination of apoA-I in human serum by radial immunodiffusion assay. Clin Chim Acta1978; 87: 387–94.
23.
BeckerWSchäferWZiegenbeinW.Die immunochemische Bestimmung der Apolipoproteine A und B: Standardisierung und Normalwerte. Laboratoriumblätter1980; 30: 56–64.
24.
VerganiCTrovatoGDioguardiN.Serum total lipids, lipoproteins cholesterol, apoproteins A and B in cardiovascular disease. Clin Chim Acta1978; 87: 127–33.
25.
BergKBørresenA.Serum high density lipoprotein and atherosclerotic heart disease. Lancet1976; i: 499–501.
26.
AlbersJJWahlPWCabanaVGQuantification of apolipoprotein A-I of human plasma HDL. Metabolism1976; 25: 633–44.
27.
NorfeldtPPOlofssonSOFagerGIsolation and partial characterization of the lipoprotein families A and A-I from HDL in human serum. Eur J Biochem1981; 118: 1–8.
28.
SteinbergKKCooperGRGraiserSRSome considerations of methodology and standardization of apolipoprotein A-I immunoassays. Clin Chem1983; 29: 415–26.
29.
GebhardtDOE. More about immunoassay of apolipoprotein A-I. Clin Chem1983; 29: 1450.
30.
MuraseTCattranDCRubensteinBInhibition of lipoprotein lipase by uremic plasma. A possible cause of hypertriglyceridemia. Metabolism1975; 24: 1279–86.
31.
KuboMMatsuzawaYYokoyamaSMechanism of inhibition of hepatic triglyceride lipase from human postheparin plasma by apolipoprotein A-I and A-II. J Biochem (Japan)1982; 92: 865–70.
32.
ShinomiyaMSasakiNBarnhartRLEffects of apoliproteins on the hepatic lipase catalyzed hydrolysis of human plasma HDL2-triacylglycerols. Biochim Biophys Acta1982; 713: 292–9.
33.
NestruckACNiedmannPDWielandHChromatofocusing of human high density lipoproteins and isolation of lipoprotein A and A-I. Biochem Biophys Acta1983; 753: 65–73.
